89bio’s Phase IIb ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks
89bio, Inc. announced positive topline data from the Phase IIb ENLIVEN trial evaluating treatment with pegozafermin in patients with NASH. In the study, both the 44mg Q2W and 30mg QW doses met, with high statistical significance.
[EMBO Journal] Using a variety of in vitro and in vivo techniques, researchers showed that metastatic prostate cancer cells acquire a specific Na+/Ca2+ signature required for persistent invasion.
[Molecular Cell] Investigators explored the role of minor intron-containing genes and minor spliceosome in cancer, taking prostate cancer as an exemplar.
[Nature Communications] The authors uncovered dual-phosphorylated form of sterol regulatory element-binding protein 1 (SREBF1), pY673/951-SREBF1 that acts as an androgen sensor, and dissociates from androgen receptor in androgen deficient environment, followed by nuclear translocation.